SCHEDULE: FMR LLC Discloses 9% Stake in Insulet Corp

FMR LLC and Abigail P. Johnson report a 9.0% beneficial ownership stake in Insulet Corp as of December 31, 2025, in an amended Schedule 13G filing.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, beneficially own an aggregate of 6,306,853.90 shares of Insulet Corp's common stock.
• This ownership represents 9.0% of the total outstanding common stock of Insulet Corp.
• FMR LLC holds sole voting power over 6,135,772.03 shares and sole dispositive power over 6,306,853.90 shares.
• Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, is deemed to have shared dispositive power over the same 6,306,853.90 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Insulet Corp.
• The filing is an Amendment No. 11 to a Schedule 13G, indicating a routine update to a previously disclosed significant stake.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. The continued significant stake by a major institutional investor like FMR LLC suggests ongoing confidence in Insulet Corp, although the passive nature means no immediate activist intent.

Positives

• The disclosure of a 9.0% beneficial ownership by a major institutional investor like FMR LLC can be interpreted as a continued vote of confidence in Insulet Corp's long-term prospects.
• The passive nature of the investment, as certified by FMR LLC, suggests a stable institutional holding without immediate intentions to influence company control.

Negatives

• The filing does not provide details on whether the 9.0% stake represents an increase or decrease from previous filings, making it difficult to assess any change in FMR LLC's conviction or strategy regarding Insulet Corp.

Risks

• The filing does not explicitly mention risks related to Insulet Corp's operations or financial health; it focuses solely on beneficial ownership disclosure.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Insulet Corp's management. It reflects FMR LLC's passive investment position as of December 31, 2025.

Management Comments

• FMR LLC certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership, particularly by large asset managers like FMR LLC (Fidelity), is a common feature in publicly traded companies. A significant, passive stake like 9.0% in Insulet Corp indicates that a major player views the company as a viable long-term investment within its portfolio, aligning with broader trends of institutional capital allocation in the healthcare technology sector.

Comparison to Industry Standards

• StockSavvy.ai observes that a 9.0% stake by a single institutional entity is a substantial holding, often placing the investor among the top shareholders. For instance, similar significant passive stakes are held by large asset managers in companies like Dexcom (DXCM) or Tandem Diabetes Care (TNDM), which operate in related diabetes technology markets. This level of ownership is consistent with major investment firms building long-term positions in established or growing companies within their investment mandates.

Stakeholder Impact

• Shareholders: The disclosure of a significant, stable institutional ownership by FMR LLC may provide a degree of confidence to other shareholders regarding the company's long-term investment appeal.
• Company Management: Awareness of a large, passive institutional holder may influence management's strategic decisions, though FMR LLC has certified no intent to influence control.

Key Dates

Keywords

Insulet Corp, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management